|Dr. Philippe Jacques Wolgen M.B.A., MBA, M.D.||CEO, MD & Director||1.27M||N/A||1963|
|Mr. Darren M. Keamy||CFO & Company Sec.||274.13k||N/A||1973|
|Dr. Dennis J. Wright||Chief Scientific Officer||218.63k||N/A||N/A|
|Mr. Malcolm Bull||Head of Investor Relations||N/A||N/A||N/A|
|Lachlan Hay||Gen. Mang. of Europe||N/A||N/A||N/A|
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PRÃNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Clinuvel Pharmaceuticals Limited’s ISS Governance QualityScore as of July 1, 2021 is 8. The pillar scores are Audit: 9; Board: 5; Shareholder Rights: 10; Compensation: 5.